Septerna (NASDAQ:SEPN) COO Sells $1,100,000.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Septerna Price Performance

Shares of Septerna stock traded down $3.05 during midday trading on Thursday, hitting $45.14. The company had a trading volume of 877,638 shares, compared to its average volume of 361,538. Septerna, Inc. has a 1-year low of $10.74 and a 1-year high of $51.10. The business’s 50 day simple moving average is $35.29 and its two-hundred day simple moving average is $29.40. The stock has a market cap of $2.11 billion, a PE ratio of -83.59 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. The firm had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.59%. On average, sell-side analysts expect that Septerna, Inc. will post -1.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SEPN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday. Wells Fargo & Company lifted their price target on shares of Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday. JonesTrading boosted their price target on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a report on Thursday. Finally, HC Wainwright increased their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.33.

Institutional Investors Weigh In On Septerna

Several large investors have recently modified their holdings of the stock. TRV GP V LLC bought a new position in shares of Septerna during the 2nd quarter worth approximately $208,160,143,000. TRV GP VI LLC bought a new stake in Septerna in the second quarter valued at $141,048,460,000. Goldman Sachs Group Inc. raised its stake in Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after acquiring an additional 1,260,409 shares in the last quarter. BlackRock Inc. acquired a new position in Septerna during the second quarter worth $64,706,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Septerna by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after acquiring an additional 104,394 shares during the period.

More Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: JonesTrading raised its price target to $62 from $43 and upgraded Septerna to “buy,” implying substantial potential upside from recent trading levels. JonesTrading raises Septerna price target
• Positive Sentiment: HC Wainwright increased its target to $60 from $40 and maintained a “buy” rating, reinforcing optimism about Septerna’s pipeline and growth prospects. HC Wainwright raises Septerna price target
• Positive Sentiment: Wells Fargo raised its target to $50 from $48 and assigned an “overweight” rating, adding to the favorable analyst consensus. Wells Fargo raises Septerna price target
• Positive Sentiment: Septerna reported quarterly revenue of $26.75 million versus expectations of $19.22 million and an adjusted loss of $0.29 per share versus the expected $0.43 loss. The earnings beat recently supported a strong rally in SEPN shares. Septerna shares rise on earnings
• Neutral Sentiment: Reported short interest was zero shares, meaning short-selling data currently provides little indication of additional buying pressure or bearish positioning.
• Negative Sentiment: Despite the positive catalysts, the stock appears to be undergoing profit-taking after its earnings-related advance. Septerna remains unprofitable, with a negative net margin and analysts expecting a full-year loss, which may be encouraging volatility after its rapid run-up.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.